Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Charles River Laboratories International, Inc. (CRL:NYSE), powered by AI.
Charles River Laboratories International, Inc. is currently trading at $187.51. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Charles River Laboratories International, Inc. on Alpha Lenz.
Charles River Laboratories International, Inc.'s P/E ratio is -64.4.
“Charles River Laboratories International, Inc. trades at a P/E of -64.4 (undervalued) with modest ROE of -4.4%.”
Ask for details →Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.
“Charles River Laboratories International, Inc. trades at a P/E of -64.4 (undervalued) with modest ROE of -4.4%.”
Ask for details →Charles River Laboratories International, Inc. (ticker: CRL) is a company listed on NYSE in the Healthcare sector (Diagnostics & Research). It has approximately 18,700 employees. Market cap is $9.3B.
The current price is $187.51 with a P/E ratio of -64.39x and P/B of 2.94x.
ROE is -4.36% and operating margin is 9.99%. Annual revenue is $4.0B.